{"schema_version":"secwatch.filing_event.v1","accession":"0001006837-24-000078","form_type":"8-K","ticker":"VATE","cik":"0001006837","company_name":"INNOVATE Corp.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.846478+00:00","generated_at":"2026-06-02T15:19:08.615477+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INNOVATE Q1 revenue $315M (-0.8%); net loss $17.7M, adj EBITDA $12.8M (+161%)","bullets":["Revenue $315.2M (down 0.8% YoY); net loss attributable to common $17.7M vs $10.2M loss in Q1 2023.","Total adjusted EBITDA $12.8M (up 161% YoY), driven by margin expansion at DBMG and cost cuts at R2.","Infrastructure revenue $307.9M, net income $4.4M; backlog $0.9B reported, $1.2B adjusted.","Life Sciences: R2 record North America system sales (400+ units); MediBeacon in ongoing FDA discussions.","Closed rights offering Apr 24: issued 5.3M common at $0.70 ($3.7M) and 31.3K preferred to Lancer ($31.3M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001006837-24-000078","json":"https://secwatch.observer/filing/0001006837-24-000078.json","markdown":"https://secwatch.observer/filing/0001006837-24-000078.md","text":"https://secwatch.observer/filing/0001006837-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006837/000100683724000078/0001006837-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006837/000100683724000078/hchc-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:19:08.615477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b133bfcf69ac681e6c129bf203880bcc3c024b6c","claim":"INNOVATE Corp. reported the quarter ended March 31, 2024 results: revenue $315.2 million, net income $17.7 million, EPS $0.22 per fully diluted share.","evidence_excerpt":"stockholders $ (0.22) $ (0.13) (69.2) % Total Adjusted EBITDA (1) $ 12.8 $ 4.9 161.2 % (1) Reconciliation of GAAP to Non-GAAP measures follows Commentary “INNOVATE delivered $315.2 million in revenue in the first quarter as the three business segments experienced a strong start to 2024,” said Avie Glazer, Chairman of INNOVATE. “Infrastructure's first quarter top","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006837/000100683724000078/0001006837-24-000078-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$315.2 million"},{"label":"Net income","value":"$17.7 million"},{"label":"EPS","value":"$0.22 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}